About Genturadx
Genturadx is a Healthcare company based in Hayward (United States) founded in 2005, and was acquired by Luminex in July 2012. Molecular diagnostic platforms for clinical PCR analysis are developed. Genturadx has raised $4.01 million across 2 funding rounds from investors including Luminex Corporation. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include NeuMoDx, Kryptos Biotechnologies and Quantalife; 3 of its 3 listed competitors have raised funding.
Company details
GenturaDx was founded in 2005 in Hayward, United States, within the molecular diagnostics sector. Platforms for clinical applications are created, including the IDBox system, which incorporates single-use disposable cassettes for PCR analysis. This integrated setup processes up to 12 patient samples at once. Assays and clinical software are also under development to support operations.
- Headquarters Hayward, United States
- Stage Acquired
- SectorsHealthcare
- Website genturadx.com
- Social LinkedIn
- Acquired by Luminex (Jul 2012)
- Total Equity Funding$4.01M (USD)
in 2 rounds
- Latest Funding Round$4.01M (USD), Series A
Apr 2011
- Investors
- Acquired byLuminex
(Jul 2012)
Funding Insights of Genturadx
Genturadx has successfully raised a total of $4.01M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.01 million completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.01M
- Total Rounds 2
- Last Round Series A — $4.01M
All 2 funding rounds of Genturadx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2011 | $4.01M | Series A | – | – | – |
| Mar 2008 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Genturadx
Genturadx has secured backing from 1 investor. Prominent investors backing the company include Luminex Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of instruments, reagents and kits for clinical diagnostics and life science research | 1995 | luminexcorp.com | Austin, United States |
Investor details for Genturadx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Genturadx
4 dated milestones of Genturadx across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Genturadx is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $4.0M.
- Exit Acquired by Luminex.
Competitors of Genturadx
Genturadx has 3 listed competitors in our database, 3 of them funded. They include NeuMoDx, Kryptos Biotechnologies and Quantalife.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neumodx.com | 2012 | Ann Arbor, United States | $66.04M | 125 | Developer of a platform for low cost molecular testing | |
| kryptosbio.com | 2017 | Hayward, United States | $12.7M | Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology. | ||
| quantalife.com | 2008 | Pleasanton, United States | $28.71M | Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. |
Detailed competitors of Genturadx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Genturadx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Genturadx
Genturadx was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Genturadx is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Genturadx is a funded company, having raised a total of $4.01M across 2 funding rounds to date.
GenturaDx was founded in 2005 in Hayward, United States, within the molecular diagnostics sector. Platforms for clinical applications are created, including the IDBox system, which incorporates single-use disposable cassettes for PCR analysis. This integrated setup processes up to 12 patient samples at once. Assays and clinical software are also under development to support operations.
Genturadx's top competitors include NeuMoDx, Quantalife and Kryptos Biotechnologies.
Genturadx has 1 investor. Key investors include Luminex Corporation.
Yes. Genturadx was acquired by Luminex in July 2012.